Comment from Eli Lilly and Company

Summary: Eli Lilly and Company supports the draft guidance as a positive step toward predictable, science-based regulation for genome editing. They provide specific recommendations to improve clarity on off-target analysis, variant-aware analysis, and long-term follow-up requirements for non-integrating products.